LOS ANGELES, May 30 /PRNewswire-FirstCall/ -- Universal Detection Technology , a developer of early-warning monitoring technologies designed to protect people from bioterrorism and other infectious health threats, announced today that it released the following corporate update from Chief Executive Officer Jacques Tizabi:
Table of contents * Marketing of BSM-2000, UDTT’s Anthrax Detectors * Increasing Threat of Terrorism * International Distribution * Expansion into Counter-Terrorism Training * Expansion into Air Monitoring for Non-Terror Related Risks Dear Shareholder:
It is unfortunate that we are living under the threat of terrorism and biological warfare. What’s of greatest concern is the lack of proper preparation at various levels for dealing with a potential attack with these deadly agents. Consequently, we have intensified our efforts to address the growing need to protect our families and businesses.
As a result of these efforts, I am pleased to report the progress we have made in the past two years. In conjunction with NASA’s Jet Propulsion Laboratory (JPL), we have successfully completed the development phase of our BSM-2000 bacterial and anthrax spore monitoring and detection device. We are now establishing our domestic and international marketing and sales programs. The purpose of this communication is to provide you with an update of our recent efforts as well as our vision of the road ahead and our future plans.
Marketing of BSM-2000, UDTT’s Anthrax Detectors
We launched a prototype of our BSM-2000, Anthrax Detection System in 2004 and have now produced a commercially available device. We have received a purchase order for two devices from a European Government and have already completed the sale of one of these units with the second one presently going through the manufacturing process. We are committed to further research for acquisition of new technologies and for enhancing the performance of BSM-2000.
In order to market the device to the US Federal Government, we have engaged Joseph Breen, and Associates to facilitate gaining access to the U.S. General Services Administration (GSA) schedule as an approved government supplier. The GSA is a federal management and procurement agency that provides products and services to the U.S. government. The GSA consists of the Federal Supply Service, the Federal Technology Service, the Public Buildings Service, the Office of Government Policy, and various Staff Offices. The GSA acts as a catalyst for more than one-fourth of the government’s total procurement dollars, according to the www.gsa.gov website.
Joseph Breen & Associates is a government contracting sales consulting firm based in Washington, DC. For companies looking for entry into the government markets, Breen & Associates provides assistance in compiling necessary information, preparing comprehensive applications, submitting applications to the GSA, and following up to obtain a contract. Please visit www.joebreen.com for additional information.
Increasing Threat of Terrorism
While Anthrax may not be in the news everyday, the threat of bioterrorism is real, and not going away anytime soon. An article that appeared last month in FederalTimes.com discussed the lack of preparedness of government agencies for an anthrax attack. Recognizing the potential role that our BSM-2000 can play, KABC Eyewitness News, an ABC-affiliate in Los Angeles, featured the product on its nightly newscast in April. Our product was also recently featured in Glendale News Press, in the March 2006 edition of IEEE Spectrum Magazine, the flagship publication of the world’s largest association of technology professionals, and in the recent issue of the NASA Spin Off magazine. More information is available in our Press Room at http://www.udetection.com/pressroom.asp.
International Distribution
As part of our BSM-2000 marketing program, we have entered into marketing and distribution agreements with Saras Sartec for Italy and Quantum Automation for Singapore. We are currently working to strengthen our relationships with our distributors in order to successfully market BSM-2000 in European and other international markets. Indeed, one of our independent distributors in Europe played a key role in the purchase order for two units of BSM-2000 from a European government.
Domestically, we have entered into key strategic alliances with Security Pro USA, and Security Solutions International (SSI). We plan to leverage these alliances to increase user awareness of the capabilities and low operational costs of BSM-2000, but also gain new sales and marketing channels by accessing our partners’ customer bases.
Expansion into Counter-Terrorism Training
We have devoted considerable time and energy to not only acquiring cutting edge technologies and developing revolutionary counter-terrorism tools and devices but also making our acquired knowledge and experience available to our partners and customers for dealing with a disaster involving biological weapons. Through the years we have developed expertise in counter-bio-terrorism technologies and disaster preparedness, including pre and post planning requirements for a disaster scenario. In recent months we have taken measures to share our expertise with facilities and building managers as well as law enforcement personnel.
As part of this effort, we have teamed up with SSI, a provider of security-related training and education services. In conjunction with SSI, earlier this year we conducted a training seminar for the Broward Sheriff’s office in Ft. Lauderdale, Florida and co-hosted an educational seminar in Washington, D.C. to provide training about technology solutions in homeland security applications for federal, state and local building managers.
Expansion into Air Monitoring for Non-Terror Related Risks
We are also examining the possibility of expanding into non-terror related airborne monitoring for certain airborne health risks. Our scientific advisory board includes Dr. Louis J. Ignarro and Dr. Leonard Makowka, who are experts in Pharmacology and hepatic sciences respectively. We believe that our technology has the potential of being adopted as a monitoring tool for bacteria build up in hospitals and operating rooms. We are dedicated to pursue this opportunity and to use all of our resources to examine the possibility of playing a major role in this market. Dr. Makowka and Dr. Ignarro both possess years of experience in medicine. Their short bios can be viewed at http://www.udetection.com/about-keypersonnel.asp.
We appreciate the continued support of our shareholders. We have recently begun to increase our investor relations activities, to increase awareness of our recent accomplishments. In conclusion, we are committed to developing and acquiring new technologies and to enhancing the performance of BSM-2000. We are excited about the direction of the Company, and look forward to sharing developments with you regarding sales, joint ventures and new agreements, products and services in the future.
Sincerely, Jacques Tizabi Chairman & CEO About Universal Detection Technology
Universal Detection Technology (UDTT), founded in 1973, is a developer of monitoring technologies, including bio-terrorism detection devices. Universal Detection Technology, in cooperation with NASA’s Jet Propulsion Laboratory (JPL) has developed the BSM-2000, a bacterial spore and anthrax spore monitoring device, which combines JPL’s spore detection technology with UDTT’s aerosol capture device. For more information, please visit http://www.udetection.com.
Forward-Looking Statements
Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company’s actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties include, among other things, the funding of amounts of capital adequate to provide for our working capital needs and our timely repayment of debt; the ability of SSI to generate sales and increase visibility of the BSM-2000 based on its contacts and relationships in the United States; our ability to timely and cost effectively complete the development and testing of our products targeted to the bio-chemical market; our ability to commercially produce our products on a profitable basis; commercial acceptance of our products; product price volatility; product demand; market competition and general economic conditions and; other factors described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company’s plans or expectations.
Universal Detection Technology
CONTACT: Jacques Tizabi of Universal Detection Technology,+1-310-248-3655, jtizabi@udetection.com; or Andrew Hellman of CEOcast,Inc., +1-212-732-4300, for Universal Detection Technology
